GCP
AVTX icon

GSA Capital Partners’s Avalo Therapeutics AVTX Stock Holding History

GSA Capital Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5
Closed -$64K – 1619
2018
Q2 		$64K Buy
+5
New +$59.6K ﹤0.01% 1614

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $445M AUM 31.98% 1-Year Est. Return

GSA Capital Partners's AVTX Position: Q3 2018 in Review

GSA Capital Partners sold out of Avalo Therapeutics (AVTX) in Q3 2018, closing a stake of 5 shares — an estimated $64K sold.

GSA Capital Partners first reported a position in AVTX in Q2 2018 and held it in 1 quarter. The position peaked at $64K in Q2 2018. 20 funds tracked by Wall St. Rank hold AVTX as of Q3 2018.

  • GSA Capital Partners reported no remaining Avalo Therapeutics position as of Q3 2018 after selling out during the quarter.
  • GSA Capital Partners sold 5 Avalo Therapeutics shares in Q3 2018, an estimated $64K.
  • GSA Capital Partners first reported a position in Avalo Therapeutics in Q2 2018 and held it in 1 quarter.
  • GSA Capital Partners's Avalo Therapeutics position peaked at $64K in Q2 2018.
  • 20 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2018.

Based on GSA Capital Partners's 13F filing for Q3 2018, filed 13 Nov 2018.